This Nvidia-Backed AI Stock Is Shrugging Off Market Pain Thanks to the FDA. Should You Buy Shares Now?
The U.S. regulatory authority wants to switch to 'more effective, human-relevant methods' instead, including machine learning and artificial intelligence, according to its press release on Friday.
FDA's announcement is driving RXRX higher as it aligns perfectly with Recursion Pharmaceuticals' core business. The biotechnology company specializes in using AI for accelerated drug discovery.
Despite today's surge, however, Recursion Pharmaceuticals stock is down nearly 55% versus its year-to-date high.
Is It Too Late to Invest in Recursion Pharmaceuticals?
FDA's announcement could help Recursion Pharmaceuticals push further to the upside as it has a massive dataset of more than 60 petabytes, which is one of the largest in the biotech space.
Recursion already counts notable names like Roche (RHHBY), Merck (MRK), and Sanofi (SNY) as partners.
And with FDA promoting the use of AI models in drug development, it's reasonable to believe that other drugmakers would want to follow suit, potentially helping RXRX shares extend gains through the remainder of 2025.
In fact, the biotech stock could climb all the way back to $11 by the end of this year, according to Gil Blum – a senior analyst at Needham.
Why Is Needham Bullish on RXRX Shares?
Recursion Pharmaceuticals came in shy of Street estimates in its latest reported quarter in February.
Still, Blum expects RXRX to nearly double from current levels as it has a promising pipeline. It's REC-617, for example, has shown encouraging results in early clinical studies.
Recursion stock will extend gains as the biotechnology company continues to advance its clinical programs and capitalize on strategic partnerships to foster innovation in 2025, he added.
Needham expects Recursion to achieve significant synergies from its $688 million Exscientia deal as well.
What's the Consensus Rating on Recursion Stock?
Other Wall Street analysts are not as bullish on Recursion Pharmaceuticals as Needham, given the consensus rating on RXRX currently sits at 'Hold.'
However, their mean target of $8.50 still represents potential upside of more than 50% from here.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
5 hours ago
- Globe and Mail
AbbVie Reports Strong Q2 2025 Financial Results
Abbvie ( (ABBV)) has released its Q2 earnings. Here is a breakdown of the information Abbvie presented to its investors. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AbbVie Inc. is a global biopharmaceutical company that focuses on discovering and delivering innovative medicines in key therapeutic areas such as immunology, neuroscience, oncology, and eye care, alongside its Allergan Aesthetics portfolio. In the second quarter of 2025, AbbVie reported a strong financial performance with an increase in net revenues and adjusted earnings per share, highlighting the company's diversified growth platform and strategic investments in innovation. Key financial metrics from the quarter include a 6.6% increase in net revenues to $15.423 billion, driven by significant growth in the immunology and neuroscience portfolios. Skyrizi and Rinvoq showed substantial revenue increases of 62.2% and 41.8%, respectively, while the neuroscience portfolio grew by 24.2%. However, the aesthetics portfolio saw a decline of 8.1% in revenues. AbbVie also announced several strategic advancements, including FDA approvals for new treatments and positive clinical trial results, which bolster its pipeline and future growth prospects. The company has raised its full-year 2025 adjusted diluted EPS guidance, reflecting confidence in continued momentum. Looking ahead, AbbVie remains optimistic about its growth trajectory, supported by its robust pipeline and strategic initiatives, as it continues to focus on delivering innovative solutions to address significant health challenges.
Cision Canada
4 days ago
- Cision Canada
AI Just Got a Green Light from the White House--Here's What That Means for Healthcare Stocks
VANCOUVER, BC, July 29, 2025 /CNW/ -- Equity Insider News Commentary – There's a lot of big voices pushing for the AI revolution to make its mark, including a new plan from the U.S. Department of Commerce to address slow-to-adopt sectors like healthcare. The comes as part of US President Trump's paper, titled Winning the Race: AMERICA'S AI ACTION PLAN, which encourages setting up regulatory sandboxes, or regulation-free environments where AI can be tested in real world scenarios with heavy oversight. As the market evaluates the opportunities available, several tech and biotech companies are already moving towards major milestones in AI-powered healthcare solutions, including Avant Technologies, Inc. (OTCQB: AVAI), Renovaro Inc. (NASDAQ: RENB), Healthcare Triangle, Inc. (NASDAQ: HCTI), GE HealthCare Technologies Inc. (NASDAQ: GEHC), and Spectral AI, Inc. (NASDAQ: MDAI). According to Accenture, AI could inject an additional $461 billion into the healthcare sector by 2035, as it surpasses the $2.26 trillion mark. Now, as AI makes its move into the healthcare space, experts are working to help guide these new solutions towards being more accurate, in a space where AI's inaccuracies (known as "hallucinations") are not an option. Thankfully, there are several players making important advancements in diagnostics, drug development, and workflow, through the use of AI. Avant Technologies, Inc. (OTCQB: AVAI) and joint-venture partner Ainnova Tech have taken a key regulatory step forward by finalizing an updated clinical trial protocol for their AI-powered Vision AI platform, following formal feedback from a mid-July pre-submission meeting with the FDA. The revised protocol, which addresses the FDA's comments, has now been presented to Fortrea, the company's contract research organization, for review. Once approved, the protocol will enable the launch of a new U.S.-based clinical trial designed to support Ainnova's goal of obtaining FDA 510(k) clearance for Vision AI in the early detection of diabetic retinopathy. "We are committed to meeting the highest regulatory standards, and we're confident that these protocol refinements will strengthen our path toward FDA 510(k) clearance," said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio. "We anticipate finalizing the clinical trial budget soon, with estimated costs coming more into focus as we refine our protocol and navigate the process." The U.S. regulatory push builds on expanding visibility for Vision AI across Latin America. In June, Vargas was featured at Roche's"Macular Spectacular" Ophthalmology Conference in Cartagena, Colombia, where he presented Vision AI as a cost-effective screening tool that can prevent diabetic blindness and improve health access in low-resource settings. He also highlighted a Q4 2024 pilot with Roche and Salud 360 that could scale across the U.S., Canada, and Europe if successful. Meanwhile, Vision AI has gone live through Grupo Dökka's Fischel and La Bomba pharmacy chains, offering walk-in screenings, real-time AI results, and direct referrals to care providers. The model eliminates the need for onsite ophthalmologists and is gaining traction with pharmacy chains, insurers, and life sciences partners. Avant and Ainnova's FDA engagement follows an earlier pre-submission meeting in July, where the agency provided clear guidance on study design and compliance. The refined clinical trial protocol, once greenlit, will guide a formal U.S. study aimed at supporting FDA clearance to market Vision AI domestically. Avant maintains global licensing rights to Ainnova's platform through Ai-nova Acquisition Corp., the JV established to commercialize Ainnova's technology portfolio. U.S. entry is viewed as a major inflection point with significant commercial potential. Looking ahead, Vision AI could serve as a frontline tool for broader disease detection. Ainnova's future roadmap includes a cloud-connected retinal camera for rural clinics and new modules aimed at identifying Alzheimer's, cardiovascular conditions, and other chronic diseases through retinal or blood biomarkers. Avant has also signaled plans for a dedicated therapeutic-focused spinout and continues to evaluate a full acquisition of Ainnova Tech under a previously announced non-binding LOI—potentially consolidating all assets and leadership under a single public platform. Renovaro Inc. (NASDAQ: RENB) secured multiple U.S. patents for its federated AI learning technologies in biomedical research. "Expanding our IP footprint in federated learning and AI-based data harmonization directly supports our long-term vision: to be the platform of choice for next-generation biomedical research and precision medicine," said David Weinstein, CEO, Renovaro. These patents support secure, privacy-preserving data integration across hospitals and labs for applications in drug discovery and precision medicine. The move strengthens Renovaro's position in the $20 billion biomedical AI space. Healthcare Triangle, Inc. (NASDAQ: HCTI) recently signed major contracts with large U.S. hospital systems and expanded its AI-powered EHR services. Its platform converts unstructured medical documents into usable data for clinicians. "These strategic wins reflect our ability to deliver enterprise-scale transformation with speed and precision," said Sujatha Ramesh, Chief Operating Officer of Healthcare Triangle." We're driving digital maturity, operational efficiency, and cost-effective care delivery - firmly positioning HCTI as a mission-critical partner, not just a service provider." The company is focused on making EHR systems smarter, more efficient, and better suited to community health networks. GE HealthCare Technologies Inc. (NASDAQ: GEHC) launched its Definium Pace Select ET, an AI-powered digital X-ray system for high-volume medical settings. "This launch reinforces our commitment to provide accessible, efficient, and high-quality care for patients, while alleviating stress from the technologist's workday by minimizing repetitive tasks and automating steps," said Jyoti Gupta, PhD, President and CEO of Women's Health and X-ray at GE HealthCare. "We remain dedicated to advancing our technology through transformative digital and AI-enabled capabilities that will remove barriers to timely and effective diagnostic imaging for any patient in need of X-ray imaging." The system automates repetitive tasks and improves image consistency to help radiologists work more efficiently. It's designed to relieve staffing pressures while maintaining high imaging standards in busy hospitals. Spectral AI, Inc. (NASDAQ: MDAI) submitted its DeepView System to the FDA for marketing approval under the De Novo pathway. "This FDA submission is a major milestone for Spectral AI and the DeepView System, representing a crucial step toward bringing this innovative diagnostic device to market in the United States," said Dr. J. Michael DiMaio, MD, Chairman of the Board at Spectral AI. "It provides clinicians with an immediate, data-driven assessment tool designed to assist clinical decision-making and may significantly improve patient outcomes." The device uses multispectral imaging and AI to predict how burn wounds will heal, helping doctors make faster and more accurate treatment decisions. It's positioned as a first-of-its-kind diagnostic tool in burn care. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
The Market Online
4 days ago
- The Market Online
Oncolytics Biotech sparks FDA discussions for potential pivotal pancreatic cancer trial
Oncolytics Biotech (TSX:ONC) has initiated regulatory discussions with the U.S. Food and Drug Administration (FDA) to advance pelareorep, its lead immunotherapeutic candidate The FDA discussions will focus on finalizing a clinical trial design that leverages pelareorep's demonstrated synergy with chemotherapy—with or without checkpoint inhibitors—and will use overall survival as the primary endpoint The company expects to move quickly and decisively down a clear regulatory path Oncolytics Biotech stock (TSX:ONC) opened trading at C$1.47 A clinical-stage immunotherapy company announced that it has initiated regulatory discussions with the U.S. Food and Drug Administration (FDA) to advance its lead immunotherapeutic candidate. Oncolytics Biotech (TSX:ONC) wants to move pelareorep into a potential registration-enabled pivotal study for first-line metastatic pancreatic ductal adenocarcinoma (mPDAC). Assuming productive engagement with the FDA, Oncolytics anticipates beginning study start-up activities before the end of 2025. This milestone underscores the company's confidence in pelareorep's differentiated mechanism of action and its promising survival signal in one of the most aggressive and underserved solid tumors. This content has been prepared as part of a partnership with Oncolytics Biotech Inc. and is intended for informational purposes only. The FDA discussions will focus on finalizing a clinical trial design that leverages pelareorep's demonstrated synergy with chemotherapy—with or without checkpoint inhibitors—and will use overall survival as the primary endpoint. Among the trial design options under consideration is an adaptive study model, potentially in collaboration with a third-party partner. The announcement follows a recent event hosted by Oncolytics, where leading experts highlighted pelareorep's potential not only in mPDAC but also in other gastrointestinal cancers, including KRAS-mutated colorectal cancer. The event reinforced the urgent need for innovative immunotherapies in pancreatic cancer, a field that has seen limited progress in recent decades. 'We expect to move quickly and decisively down a clear regulatory path,' Jared Kelly, Chief Oncolytics' CEO said in a media statement. 'This is about execution and focus. Our goal is to win on survival—and this pivotal study is how we do it. We believe this program not only creates significant value for shareholders but also positions Oncolytics as a highly attractive partner for pharma companies seeking to break open the immunotherapy landscape in mPDAC and other GI tumors.' Pelareorep has already received both fast track and orphan drug designations from the FDA for mPDAC, and translational data continue to support its immunologic activity. These regulatory advantages, combined with compelling clinical data, position Oncolytics as an attractive partner for companies seeking to expand their GI oncology pipelines. Oncolytics Biotech is a clinical-stage biotechnology company developing immunotherapies against breast, anal and pancreatic cancer. Oncolytics Biotech stock (TSX:ONC) opened 0.66 per cent lower trading at C$1.47, but it has climbed 20.38 per cent since the year began and is up 4.76 per cent since this time last year. Join the discussion: Find out what the Bullboards are saying about Oncolytics Biotech and check out Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here .
